安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- KRAS - Wikipedia
KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS MAPK pathway The protein relays signals from outside the cell to the cell's nucleus
- What’s new in KRAS mutation research? | UT MD Anderson
The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers
- KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune . . .
KRAS mutations promote oncogenic signaling and modify the tumor microenvironment (TME), promoting immune evasion and tumor growth These alterations lead to treatment resistance, highlighting the importance of targeted therapies in KRAS-driven cancers
- Type of KRAS mutation may guide more effective cancer treatments
Up to a third of patients with lung adenocarcinoma, the most common form of lung cancer, have KRAS mutations that are thought to be responsible for tumor development and growth
- Exploring KRAS: A precision approach in oncology - Merck
KRAS is one of the most frequently mutated oncogenes found in cancer In healthy cells, KRAS serves as an on-off switch that regulates cell growth However, when the gene is mutated, KRAS can become stuck in the “on” position, causing uncontrolled cancer cell growth and proliferation
- First-in-Class Investigational Drug KRAS G12D Degrader Shows Promise in . . .
Researchers have known for decades that mutations in the RAS gene can drive cancer This happens because KRAS mutations send a continuous signal to cells, directing them to divide and multiply uncontrollably
- KRAS Mutation: Pancreatic, Colon, Lung Cancer Testing Results
KRAS mutations can affect pancreatic, lung, colon and other cancer treatments Learn how common it is, about testing and what results mean
- Targeting KRAS mutations: orchestrating cancer evolution and . . .
In this review, we provide a brief overview of KRAS mutations in cancers and tumorigenesis, specifically focusing on currently approved therapies for targeting KRAS, ongoing advances,
|
|
|